<i>In Silico</i> Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
Coronaviruses (CoVs) have recently emerged as significant causes of respiratory disease outbreaks, with the novel coronavirus pneumonia of 2019, known as COVID-19, being highly infectious and triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding virus–host interact...
Saved in:
| Main Authors: | Islam Alagawani, Feng Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/15/12/6544 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Marine-Derived Peptides from <i>Phaeodactylum tricornutum</i> as Potential SARS-CoV-2 Mpro Inhibitors: An <i>In Silico</i> Approach
by: David Mauricio Cañedo-Figueroa, et al.
Published: (2025-05-01) -
Molecular Recognition of SARS-CoV-2 Mpro Inhibitors: Insights from Cheminformatics and Quantum Chemistry
by: Adedapo Olosunde, et al.
Published: (2025-05-01) -
Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation
by: Mohammad Hossein Haghir Ebrahim Abadi, et al.
Published: (2025-07-01) -
Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
by: Qian Wang, et al.
Published: (2024-10-01) -
Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19
by: Karol Biernacki, et al.
Published: (2024-12-01)